Dynavax Technologies (DVAX) Reports Q3 loss of $0.24
More News related to DVAX
- Dynavax Completes Enrollment of First Cohort of Patients in Phase 1b Clinical Trial for Hepatitis B Therapy
- Dynavax Technologies (DVAX) To Purchase Symphony Dynamo; Will Acquire $20M in Cash and Hep C and Cancer Rights
- Dynavax to Acquire Symphony Dynamo, Inc., Including $20 Million in Unrestricted Cash
- Dynavax Appoints Francis R. Cano, Ph.D. to Board of Directors
- Dynavax's HEPLISAV Shows Increased Protection Rate for Chronic Kidney Disease Patients
More News related to Earnings
- Notable ETF Movers 12/01: FXI, EWJ, GDX, BHH Up; FXY, UUP Lower
- Notable Analyst Rating Changes 12/01: FITB, BPFH, MENT, CLWR, LTD, SPWRA Upgraded; NFLX, NUVA Downgraded
- Notable Mergers and Acquisitions of the Day 12/1: GE/CMCSA, GMCR/PEET, IT, BLK
- Morning Movers 12/01: PEIX, SYMX, GSIT, HDY, GES, BPFH Higher; LTON, OVTI, PLX Lower
- After-Hours Movers 11/30: GES, ALTR Higher; NLST, CUTR, LTON, OVTI Lower
Dynavax Technologies Corporation (Nasdaq: DVAX) reports Q3 loss of $0.24, versus the analyst estimate of ($0.16). Revenue for the quarter was $2.90 million, which compares to the estimate of $6.70 million.
Related Categories
EarningsStocks Mentioned
-0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
